COVID-19 Vaccine Booster Shot Preserves T Cells Immune Response Based on Interferon-Gamma Release Assay in Inflammatory Bowel Disease (IBD) Patients on Anti-TNFα Treatment.
anti-SARS-CoV-2 immunogenicity
anti-TNFα agents
cellular immune response
humoral immune response
inflammatory bowel disease
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
03 Mar 2023
03 Mar 2023
Historique:
received:
30
12
2022
revised:
20
02
2023
accepted:
01
03
2023
medline:
31
3
2023
entrez:
30
3
2023
pubmed:
31
3
2023
Statut:
epublish
Résumé
Immune-modifying treatment in inflammatory bowel disease (IBD) impairs the humoral response. The role of T lymphocytes in this setting is still unclear. This study aims to assess if a booster shot (third dose) of BNT162b2 mRNA COVID-19 vaccine enhanced the humoral response and elicited cellular immunity in IBD patients on different immuno-therapy regimens compared to healthy controls (HCs). Five months after a booster dose, serological and T-cell responses were assessed. The measurements were described using geometric means with 95% confidence intervals. The differences between study groups were assessed by Mann-Whitney tests. Seventy-seven subjects (
Identifiants
pubmed: 36992175
pii: vaccines11030591
doi: 10.3390/vaccines11030591
pmc: PMC10051087
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Rev Recent Clin Trials. 2022 Jun 28;:
pubmed: 35770406
Int Immunopharmacol. 2021 Nov;100:108095
pubmed: 34619529
J Crohns Colitis. 2022 Feb 23;16(2):251-258
pubmed: 34379729
Clin Gastroenterol Hepatol. 2007 Jul;5(7):851-6
pubmed: 17544875
Vaccines (Basel). 2020 Aug 14;8(3):
pubmed: 32824111
Biochem Biophys Res Commun. 2021 Jan 29;538:211-217
pubmed: 33190827
Lancet Gastroenterol Hepatol. 2022 Nov;7(11):1005-1015
pubmed: 36088954
Inflamm Bowel Dis. 2014 Jan;20(1):69-74
pubmed: 24284413
J Crohns Colitis. 2022 Sep 8;16(9):1347-1353
pubmed: 35358307
N Engl J Med. 1987 Dec 24;317(26):1625-9
pubmed: 3317057
Aliment Pharmacol Ther. 2018 Jan;47(2):162-175
pubmed: 29205406
Lancet Gastroenterol Hepatol. 2022 Apr;7(4):342-352
pubmed: 35123676
Biomedicines. 2022 Jan 13;10(1):
pubmed: 35052849
Mediators Inflamm. 2015;2015:326032
pubmed: 25944980
Lancet. 1980 Apr 19;1(8173):876
pubmed: 6103229
Lancet. 2017 Apr 29;389(10080):1756-1770
pubmed: 27914657
Nat Commun. 2022 Mar 16;13(1):1379
pubmed: 35296643
Nat Rev Gastroenterol Hepatol. 2023 Jan;20(1):50-64
pubmed: 35945456
Med Clin (Barc). 2022 Aug 12;159(3):116-123
pubmed: 34666900
Gut. 2021 May;70(5):865-875
pubmed: 33753421
J Crohns Colitis. 2014 Mar;8(3):223-33
pubmed: 24011513
Am J Gastroenterol. 2010 Jan;105(1):148-54
pubmed: 19755964
Dig Liver Dis. 2023 Feb;55(2):154-159
pubmed: 36127228
Inflamm Bowel Dis. 2012 Jun;18(6):1042-7
pubmed: 21674732
Gut. 2015 Jan;64(1):77-83
pubmed: 24763133
Nature. 2021 Feb;590(7847):630-634
pubmed: 33276369
Lancet Gastroenterol Hepatol. 2021 Dec;6(12):1002-1014
pubmed: 34688373
N Engl J Med. 2009 Nov 19;361(21):2066-78
pubmed: 19923578
PeerJ. 2021 Oct 27;9:e12100
pubmed: 34760342
Clin Gastroenterol Hepatol. 2022 Jul;20(7):1456-1479.e18
pubmed: 35189387
Clin Infect Dis. 2021 Dec 6;73(11):2145-2147
pubmed: 33825869
Lancet. 2017 Apr 29;389(10080):1741-1755
pubmed: 27914655
Clin Microbiol Infect. 2021 Sep;27(9):1371-1373
pubmed: 34111582
Inflamm Bowel Dis. 2022 Jul 1;28(7):1130-1133
pubmed: 35397000
Am J Gastroenterol. 2009 Feb;104(2):444-53
pubmed: 19174786
Gastroenterology. 2021 Oct;161(4):1340-1343.e2
pubmed: 34144046
Front Med (Lausanne). 2021 Dec 20;8:765474
pubmed: 34988090
Infect Dis Ther. 2021 Dec;10(4):2765-2776
pubmed: 34435336
Inflamm Bowel Dis. 2018 Jan 18;24(2):380-386
pubmed: 29361083
Medicina (Kaunas). 2020 Aug 13;56(8):
pubmed: 32823727
Clin Gastroenterol Hepatol. 2022 Jul;20(7):1609-1612.e1
pubmed: 34998996